



54. A compound of formula (XIV)



wherein R^3 , R^4 , R^5 and R^6 are as defined in claim 29 and R' represents a hydroxy functionalised polystyrene resin.

55. A compound of formula (XXI)




wherein R^1 , R^2 , R^4 , R^5 , R^6 and d are as defined in claim 29, R' represents a hydroxy functionalised polystyrene resin and Hal represents halogen.

REMARKS

Applicant has attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information. Claims 1-28 have been canceled and replaced with claims 29-55 and for which no new matter has been added. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted;

Date: June 18, 2001

By: 


Charles E. DADSWELL
Attorney of Record, Reg. No 35,851

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2370

Compounds Useful in the Treatment of Inflammatory Diseases

Abstract

There are provided according to the invention, novel compounds of formula (I)



wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.